KAWASE Mitsuo Nippon Gaishi Co. Ltd., Chief research fellow, 環境装置事業部・バイオ研究課, 課長
KONDO Hirosato Kanebo Pharmaceutical Co. Ltd., Group reader, 創薬研究所・化学研究部, グループ長
ISHIDA Hideharu Gifu University, Faculty of Agriculture, Associate Professor, 農学部, 教授 (20203002)
|Budget Amount *help
¥6,300,000 (Direct Cost : ¥6,300,000)
Fiscal Year 1999 : ¥1,200,000 (Direct Cost : ¥1,200,000)
Fiscal Year 1998 : ¥5,100,000 (Direct Cost : ¥5,100,000)
1. Studies on novel, endogenous ligand for selectins, and molecular design for selectin blockers: We have found that GSC-150, a selectin blocker, would be useful for treatment of allergies such as atopic dermatitis, and have developed an efficient procedure for mass production of GSC-150. 6-Sulfo sialyl LeィイD1XィエD1 has been found to be an endogenous ligand for L-selectin on high endothelial venules (HEV) of human lymph nodes (J. Biol. Chem., 273, 11225-11233. 1998), and very recently, a novel 6-sulfo de-N-acetyl sialyl LeィイD1XィエD1 has been discovered to be a superior ligand for L-selectin (Angew. Chem. Int. Ed., 38, 1131-1133, 1999).
2. Studies on α-series (Chol-1) gangliosides, and structure-activity relationship for MAG binding: We have succeeded in an efficient, total synthesis of GT1aα (Glycoconjugate J., in press), and have demonstrated that the internal sialic acid α(1-6)-linked to GalNAc might be replaced by other anionic substituents such as sulfate (Carbohydr. Res., 316, 1-5, 1999; J. Biol. Chem., in press).
Based on these new findings, design and synthesis of novel medicines and biomaterials are now proceeding.